hemodialysis
Conditions
Interventions
Group A:HFR-q2w group: Received standard HD treatment, with HFR treatment administered once every two weeks as a substitute for HD treatment.
Group B:HAHD-q2w group: Received standard HD treatment, with HAHD treatment replacing HD treatment once every two weeks.
Sponsors
Naval Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged =18 years, with no gender restriction 2.Receiving hemodialysis three times per week for more than 3 months 3.Using a well-functioning arteriovenous fistula with two needles or a long-term tunneled cuffed dual-lumen catheter (blood flow rate >250 mL/min) 4.Voluntarily signing the informed consent form
Exclusion criteria
Exclusion criteria: 1.Concomitant peritoneal dialysis 2.Severe cardiac, pulmonary, or cerebrovascular disease 3.Severe bleeding disorders (cerebral hemorrhage, gastrointestinal bleeding, retinal hemorrhage) 4.Patients with refractory hypotension (systolic blood pressure less than 90 mmHg) 5.Severe infection, active malignant tumor 6.Life expectancy less than two years, platelet count less than 60 x 10^9/L 7.Unable to eat orally 8.Allergy to the HFR or HA device 9.Ongoing participation in other clinical trials 10.Other reasons deemed by the investigator as inappropriate for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| P-cresyl sulfate;Indoxyl sulfate;Pruritus score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Parathyroid hormone;ß2-microglobulin;interleukin-6;Sleep quality score;cardiovascular event;cerebrovascular events;all-cause mortality event;adverse event; | — |
Countries
China
Contacts
Public ContactZewei Chen
Department of Nephrology, Naval Medical Center
Outcome results
None listed